Ravi Biolife is an API manufacturer based in India. It holds 3 active US drug master files and 4 valid CEPs across a filed portfolio of 5 molecules. Its filings concentrate with EEC_EAEU and MINSA (CR). Customs aggregates show $180K of exports covering 32 molecules to 9 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Mumbai, India | Not on file |
| Raigad, India | 3027545288 |
| Mumbai, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Gemcitabine | EDQM, US FDA | 2 |
| Methotrexate | EDQM, US FDA | 2 |
| Nilotinib | EDQM | 1 |
| Pemetrexed | US FDA | 1 |
| Pemetrexed Disodium | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| EEC_EAEU | 3 | None |
| MINSA (CR) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $47K | 3 |
| 2025 | Not reported | $180K | 9 |
| 2024 | Not reported | $58K | 4 |
| 2023 | Not reported | $2K | 1 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Ravi Biolife comes back tiered against every other supplier able to file there.
Start for free